Monoclonal TCR-redirected tumor cell killing

Nathaniel Liddy(Immunocore (United Kingdom)), Bent K. Jakobsen(Mission Therapeutics (United Kingdom)), Carl H. June(University of Pennsylvania), Nikolai M. Lissin(Immunocore (United Kingdom)), Nicholas J. Pumphrey(Adaptimmune (United Kingdom)), Gabriela Plesa(University of Pennsylvania), Annelise Vuidepot(Immunocore (United Kingdom)), Samantha Paston(Immunocore (United Kingdom)), Katherine J. Adams(Immunocore (United Kingdom)), Daniel Williams(Immunocore (United Kingdom)), Michael Kalos(Pillar College), Rebecca Dennis(Immunocore (United Kingdom)), Deborah H. Sutton(Immunocore (United Kingdom)), Yvonne McGrath(Immunocore (United Kingdom)), Kristin Ladell(Cardiff University), Emma Gostick(University Hospital of Wales), Peter Molloy(AXON Neuroscience (Slovakia)), Giovanna Bossi(Immunocore (United Kingdom)), Frayne Bianchi(Immunocore (United Kingdom)), Naomi E. Harwood(Immunocore (United Kingdom)), Brian Cameron(Immunocore (United Kingdom)), Jessie Gavarret(Immunocore (United Kingdom)), Yi Li(Shanghai University of Traditional Chinese Medicine), David A. Price(University Hospital of Wales), Tara Mahon(Immunocore (United Kingdom)), Namir J. Hassan(Immunocore (United Kingdom)), Emma Baston(Immunocore (United Kingdom)), Anna Lissina(At Bristol), Malkit Sami(Immunocore (United Kingdom)), Jane Harper(Immunocore (United Kingdom)), Penio Todorov(Immunocore (United Kingdom)), A. Johnson(Immunocore (United Kingdom)), Rebecca Ashfield(Immunocore (United Kingdom)), Steve M. Dunn(Immunocore (United Kingdom)), Andrew K. Sewell(Cardiff University)
Nature Medicine
May 6, 2012
Cited by 324


Related Papers